Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Evaluation of posterior chamber phakic IOL diameter with anterior segment OCT

Poster Details

First Author: G.Baikoff FRANCE

Co Author(s):    E. Fuentes   J. Alfonso-Sanchez   C. Fuentes        

Abstract Details



Purpose:

The authors carried out a retrospective study on 250 eyes implanted with collagel posterior chamber phakic implants with a central hole for the circulation of aqueous humor. They considered myopic eyes and excluded hyperopic and toric eyes. The aim was to find out whether the anterior segment OCT was as reliable as the ultrasound devices or the white-to-white method in choosing the diameter of the lens and predicting the IOL vaulting.

Setting:

Clinique Monticelli, 88 rue du Cdt Rolland, 13008 Marseille, France + Instituto Oftalmologico Fernandez-Vega, Avda Dres Fernandez-Vega S/N 33012 OVIEDO-ASTURIAS, Spain

Methods:

The study was done on 250 myopic eyes, (mean: -9D - range – 1.50D to -25D). The parameters analyzed were the internal diameter of the anterior chamber (angle to angle), the crystalline lens rise, anterior chamber depth (endothelium to crystalline lens) and the lens power.

Results:

By using a mathematical formula borrowed from astronomical physics (framework of Bayesion analysis using Markov Chain Monte Carlo (MCMC) simulations), a relationship was established enabling us to predict the lens diameter and thus its vaulting with a precision of ±300ṁm in 90% of cases

Conclusions:

The anterior segment OCT cannot explore the sulcus but from the structures situated in front of the iris, the device gave equivalent, sometimes better results than the other techniques (white-to-white, or UBM). The advantage lies in the preoperative simplicity of the technique enabling us to choose the implant and predicting the safety distance lens/crystalline lens (vaulting) in 90% of cases

Financial Disclosure:

NONE

Back to previous